Novartis: Dyskinesias trials

The registry lists 12 Dyskinesias studies with Novartis as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 2 10Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa TherapyCompletedNCT00099268Phase 3Results posted
• Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01491932Phase 2
• Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01491529Phase 2
• Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseCompletedNCT01474421Phase 2
• Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01385592Phase 2
• Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01173731Phase 2
• Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced DyskinesiaCompletedNCT01092065Phase 2
• Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing ChoreaTerminatedNCT01019473Phase 2
• Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseCompletedNCT00986414Phase 2
• Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease PatientsCompletedNCT00888004Phase 2
• Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopaCompletedNCT00582673Phase 2
• A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/LevodopaCompletedNCT00134966Phase 3